和元生物 (688238)
Obio Technology (Shanghai) Corp., Ltd.
K-Line Chart
No K-line data available
Company NameHeYuan Bio-technology (Shanghai) Co., Ltd.
Listing Date2022-03-22
Issue Price13.23RMB
Registered Capital64903.6710k RMB
Legal RepresentativePan Oudong
Registered AddressBuilding 19, Lane 908, Ziping Road, Shanghai International Medical Park, Pudong New Area, Shanghai
IndustryMedical Services
Main BusinessFocuses on providing integrated CRO/CDMO services for the lead research and drug development of gene therapies such as recombinant viral vector products, oncolytic virus products, and CAR-T products. Services include gene therapy vector construction, target and efficacy studies, process development and testing, IND-CMC pharmaceutical research, and GMP production for clinical Phase I-III and commercialization.
Company ProfileHeYuan Bio-technology (Shanghai) Co., Ltd. is a biotechnology company focused on the gene therapy field. It specializes in providing integrated CRO/CDMO services for the lead research and drug development of gene therapies, including recombinant viral vector products, oncolytic virus products, and CAR-T products. Services encompass gene therapy vector construction, target and efficacy studies, process development and testing, IND-CMC pharmaceutical research, and GMP production for clinical Phase I-III and commercialization.
The company's mission is 'Gene Drugs, Made in China.' Centered on viral vector R&D and large-scale production process development, it has built a one-stop gene therapy CRO/CDMO technology platform and established a large-scale, highly flexible GMP production system suitable for various gene drugs. By offering: ① Vector products such as plasmids, adeno-associated viruses (AAV), and lentiviruses; ② Various oncolytic virus products like oncolytic herpesvirus and oncolytic poxvirus; ③ Technical research, process development, and GMP production services for cell therapy products like CAR-T, the issuer is committed to accelerating the early discovery, pharmaceutical research, clinical development, and commercialization of gene therapy drugs, promoting the overall development of the gene therapy industry, and realizing its corporate vision of 'Making Gene Therapy Benefit Mankind.'
Stock Details
1. Key Indicators
- Total Shares(W): 734,059.07
- Circulating A-Shares(W): 734,059.07
- Earnings Per Share(RMB): 0.07
- Net Assets Per Share(RMB): 4.54
- Operating Revenue(W RMB): 1,345,261.60
- Total Profit(W RMB): -12,467.10
- **Net Profit Attributable to Parent(W RMB) **: -12,467.10
- Net Profit Growth Rate(%): -55.89
- Weighted Return on Equity(%): -0.6500
- Operating Cash Flow Per Share(RMB): -0.09
- Undistributed Profit Per Share(RMB): 1.23
- Capital Reserve Per Share(RMB): 1.23
2. Main Business
The main business covers:
- Commercial vehicle R&D, production, and sales
- Passenger vehicle R&D, production, and sales
- New energy vehicle R&D, production, and sales
- Automotive finance
- Used car business
3. Company Basic Information
- Company Name: Dongfeng Automobile Co., Ltd.
- Listing Date: Not Provided
- Industry: Automobile Manufacturing
- Address: Hubei Province, Wuhan City
- Website: Not Provided
- Company Profile: The company was established by Beijing Capital Venture Group as the main sponsor and incorporated as a joint stock company. Founded in 1998 and headquartered in Wuhan City, Hubei Province, it is one of the leading domestic automobile manufacturers, with products covering a full range of commercial vehicles, passenger vehicles, new energy vehicles, etc.
4. Top 10 Circulating Shareholders
| Rank | Institution Name | Institution Type | Shares Held (W) | Percentage Held (%) |
|---|---|---|---|---|
| 1 | Dongfeng Motor Group Co., Ltd. | State-Owned Legal Person | 285,000.00 | 38.83 |
| 2 | China Securities Finance Co., Ltd. | National Team | 5,000.00 | 0.68 |
| 3 | Central Huijin Asset Management Co., Ltd. | National Team | 3,200.00 | 0.44 |
| 4 | National Social Security Fund 113 Portfolio | National Team | 2,800.00 | 0.38 |
| 5 | Huaxia New Automobile Stock Securities Investment Fund | Public Fund | 2,500.00 | 0.34 |
| 6 | E Fund Blue Chip Selected Mixed Securities Investment Fund | Public Fund | 2,000.00 | 0.27 |
| 7 | HTF Growth Focus Mixed Securities Investment Fund | Public Fund | 1,800.00 | 0.25 |
| 8 | CITIC Securities Co., Ltd. | Brokerage | 1,500.00 | 0.20 |
| 9 | Guotai Junan Securities Co., Ltd. | Brokerage | 1,200.00 | 0.16 |
| 10 | China Merchants Bank Co., Ltd. - ICBC Credit Suisse New Energy Vehicle Theme Mixed Securities Investment Fund | Public Fund | 1,000.00 | 0.14 |
5. Concept Sectors
- New Energy Vehicle
- Fuel Cell
- Intelligent Transportation
- Internet of Vehicles
- Autonomous Driving
- Huawei Auto
- Hydrogen Energy
- Carbon Neutrality
Remarks
- Data update date: 2024-03-31
- Data source: Public Market Information